0001193125-26-131928
SEC filingRenovoRx delivered strong revenue growth in FY2025 from increased adoption and repeat use of RenovoCath, but expanded operating losses reflect continued investment in commercial infrastructure amid ongoing clinical development.
RenovoRx generated $1.1 million in revenue during FY2025, a significant increase from $43.0 thousand in FY2024. This growth was primarily driven by increased utilization of the RenovoCath system across existing customers, with more cancer patients undergoing multiple procedures leading to repeat purchase orders. Additionally, new institutions adopted the device, including several high-volume National Cancer Institute-designated centers, signaling growing clinical confidence and market penetration.
Net cash used in operating activities totaled -$10.97M, slightly higher than the prior year’s -$9.13M, reflecting the ongoing funding needs of commercial scaling. Capital expenditures were minimal at $2,000, down from $12,000 in FY2024, resulting in free cash flow of -$11.0M. The close alignment between net loss and cash outflow highlights the absence of large non-cash distortions and confirms that losses are primarily driven by real operating investments.
The company continues to face net losses, which are expected to persist as it advances its Phase III TIGeR-PaC trial and expands commercial activities. Management anticipates further increases in selling, general and administrative expenses due to continued hiring in sales and marketing. The inability to raise capital as needed would negatively impact liquidity and the ability to execute its business strategy, emphasizing ongoing reliance on external financing to support both clinical and commercial objectives.